ImportantUpdates
CORONA Remedies board met and approved Q1 financial results.
CORONA Remedies LimitedCORONA · Filed with the exchange
Revenue grew 21.9% YoY to ₹422.4 Cr, PAT up 30.1% YoY to ₹60.1 Cr.
The company inaugurated an EU-GMP approved Female Hormone Facility and integrated the Wokadine brand.
No comments yet. Be the first.